All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL: A 5-year follow-up study
Here, we summarize a 5-year follow-up of the phase II study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in patients...
HOVON NHL 24 trial: Rituximab plus MBVP in PCNSL
Here, we summarize a study reporting on 82.3 months follow-up data from the HOVON NHL 24 trial published by Bromberg et al. in Neuro-oncology.